©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Analysis of the Growth and Transformation Suppressor Domains of Promyelocytic Leukemia Gene, PML(*)

(Received for publication, August 18, 1995; and in revised form, October 30, 1995)

Xiao-Feng Le Peirong Yang Kun-Sang Chang (§)

From the Division of Laboratory Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

The promyelocytic leukemia gene (PML) involved in the t(15;17) (q22;q12) translocation in acute promyelocytic leukemia is a growth suppressor. To elucidate the functional domains of PML, several mutants lacking the nuclear localization signal (PMLnls-), the dimerization domain (PMLdim-), the proline-rich domain at the N-terminal (PMLpro-), the proline-rich RING finger motif (PMLpr-), the proline-rich RING finger B-box-1 (PMLprb-), the serine-proline-rich domain at the C-terminal (PMLsp-), and the double mutant (PMLprb-nls-) have been constructed. Immunofluorescence staining of transiently transfected NIH3T3 cells demonstrated that the RING finger motif, dimerization domain, and nuclear localization signal are all required for the formation of PML oncogenic domains (PODs). Immunofluorescence staining of transiently transfected GM637D human fibroblasts indicated that expression of PMLprb-, PMLnls-, and PMLprb-nls- led to a significant reduction or, in some cases, complete elimination of PODs. PMLdim-, PMLnls-, PMLpr-, PMLprb-, and PMLprb-nls- mutants were found to lose their ability to suppress transformation of NIH3T3 cells by activated neu, while PMLpro- and PMLsp- mutants did not. These results suggest that the ability of PML to form a POD is essential for suppression of growth and transformation. Furthermore, since PMLprb-, PMLnls-, and PMLprb-nls- mutants could block the suppression effect of wild-type PML on transformation of NIH3T3 cells by the neu oncogene, these PML mutants are potential dominant negative inhibitors of PML. Our study also suggests that the RING finger motif may interact with other nuclear proteins.


INTRODUCTION

The nonrandom chromosomal translocation t(15;17) is a cytogenetic hallmark of acute promyelocytic leukemia (APL)(^1)(1) , and the genes involved at the breakpoint site have been cloned and characterized (2, 3, 4, 5, 6, 7, 8, 9, 10, 11) . It is now clear that the t(15;17) translocation fuses the retinoic acid receptor-alpha (RARalpha) gene on chromosome 17 and the PML gene on chromosome 15. Fusion genes PML-RARalpha and RARalpha-PML transcribe fusion transcripts and encode potentially oncogenic fusion proteins. Since most of the functional domains of both PML and RARalpha are retained in the fusion protein PML-RARalpha, it is speculated that PML-RARalpha is critical for the pathogenesis of APL. Indeed, in cotransfection assays, it was found that PML-RARalpha represses RA-responsive promoters in the absence of RA(5, 6, 7, 9) . The stable expression of PML-RARalpha inhibits apoptosis in U937 cells and makes these cells unable to respond to differentiation induction by 1,25-dihydroxyvitamin D(3) (vitamin D(3)) and transforming growth factor beta(1)(12) . In addition, stable expression of PML-RARalpha in K562 cells interferes with erythroid differentiation induced by hemin(13, 14) . Thus, expression of this fusion protein in APL cells may be responsible for blocking differentiation and prolonging survival of promyelocytes.

PML-RARalpha can effectively sequester PML and the retinoic X receptor (RXR)(7, 15, 16, 17) . In APL cells, double-color immunofluorescence staining of PML, RXR, and PML-RARalpha demonstrated that both PML and RXR colocalize with PML-RARalpha in vivo(16) . However, after all-trans-retinoic acid (ATRA) induced differentiation of the APL cells, PML and RXR no longer colocalized with PML-RARalpha, indicating that sequestration of PML and RXR by the PML-RARalpha fusion protein is critical for the development of APL. This notion is strongly supported by our recent finding that PML is a growth suppressor(18) . In brief, we found that (i) increased expression of PML in the APL cells results in a loss of clonogenicity in soft agar assay and tumorigenicity in nude mice(18) ; (ii) PML suppresses the transformation of rat embryo fibroblasts by cooperative oncogenes and of NIH3T3 cells by activated neu(18, 19) ; (iii) PML is a promoter-specific transcription suppressor, suppressing the promoter activity of the epidermal growth factor receptor and multidrug-resistance genes and having little effect on the promoters of beta-actin, SV-40, and Rous sarcoma virus(18) . From this study and others, we hypothesized that PML-RARalpha plays a central role in APL as a dominant negative inhibitor of the normal function of PML (growth suppressor) and RXR (coregulator of RAR, thyroid hormone, vitamin D receptor, etc.) and consequently leads to the development of APL by growth stimulation and loss of differentiation induction by hormone or growth factors.

PML is a member of the family of RING finger proteins capable of forming a homodimer through the dimerization domain(20) . As shown by immunofluorescence staining, PML accumulates in the nucleus in a speckled pattern composed of nuclear bodies called PML oncogenic domains (PODs)(17) . PODs are also known as ND10 (21) or Kr bodies (16) . PML is believed to colocalize with the autoantigens in primary biliary cirrhosis, but the two proteins are not directly known to interact with each other(16, 17, 22) . It is speculated that PML first interacts with other unknown protein factors and then is indirectly associated with the autoantigens. This type of PML-associated protein factor has yet to be identified. In APL cells induced to differentiated by ATRA, the abnormal microspeckled PML pattern can be reorganized to the normal PODs(16, 17) . In RA-resistant, APL-derived NB4 cells, POD formation cannot be induced by ATRA treatment(17) . Together, these results indicate that the ability of PML to form PODs is required for the induction of differentiation in APL cells.

Taking advantage of the fact that PML can suppress the formation of NIH3T3 cell foci by activated neu(18, 19) , we have constructed several PML mutants and examined their ability to form PODs in vivo and suppress transformation. Here, we demonstrate that PML mutants lacking the nuclear localization signal, the dimerization domain, and the RING finger domain are unable to form PODs and that their ability to suppress foci formation is significantly reduced. However, mutants lacking the proline-rich domain at the N-terminal and the serine-proline-rich domain on the C-terminal can form PODs in vivo and can suppress foci formation, much like the wild-type PML. Our results corroborate the previous finding that the ability of APL cells to reassemble PODs after ATRA treatment is an important event in differentiation induction(17) . Furthermore, we show that PMLprb-, PMLnls-, and PMLprb-nls- are potential dominant negative inhibitors of PML and that the RING finger motif may interact with other nuclear proteins.


MATERIALS AND METHODS

Plasmid Construction

The PML expression plasmid pSG5PML, as described in our previous report(18) , was used to construct PML deletion mutants. Mutant PMLnls- (see Fig. 1) was created by digesting pSG5PML with MluI and SmaI, blunt ended with a Klenow fragment, and circularized with T4-DNA ligase. Mutant PMLsp- was constructed by digesting pSG5PML with MluI and BamHI and then blunt ended and circularized with T4-DNA ligase. Mutant PMLdim- was constructed by completely digesting pSG5PML with KpnI, then ethanol precipitated, resuspended in high stringency S1 buffer (200 mM NaCl, 50 mM sodium acetate, pH 4.5, 1 mM ZnSO(4), 0.5% glycerol), and treated with 3000 units of S1 nuclease (Life Technologies, Inc.)/ml at 37 °C for 30 min. The linearized plasmid was further treated with the Klenow fragment and circularized with T4-DNA ligase. Clones with an in-frame deletion were identified by direct DNA sequencing and retained. A clone lacking PML nucleotides 684-888(8) , a sequence that encodes the entire putative leucine zipper, was designated PMLdim-. Deletion mutants PMLpro-, PMLpr-, and PMLprb- were constructed by polymerase chain reaction amplification of pFM211 (the original cDNA clone used to construct pSG5PML(18) ) using the following primers: MU1, 5`-AAGGATCCACCATGGAGGAGGAGTTCCAGTT-3`; MU2, 5`-GAGGATCCACCATGGATAACGTCTTTTTCG-3`; MU3, 5`-AAGGATCCACCATGGTGCGTGAGTTCCTGGA-3`; PMD, 5`-CGATGCAATTGAGGGTGCAA-3`. The underlined regions indicate the position of the perfect Kozak sequence (23) being incorporated into the upstream primer to generate the translation initiation site. To minimize the possibility of mutation, polymerase chain reaction amplifications were carried out by KlenTaq 1 and Pfu polymerases in a 15:1 ratio as described by Barnes(24) . Primer sets MU1/PMD, MU2/PMD, and MU3/PMD were used to generate mutant cDNAs of PMLpro-, PMLpr-, and PMLprb-, respectively. The cDNA was digested with the restriction endonuclease BamHI, purified on a Centricon-100 spin column (Amicon Inc., Beverly, MA), and inserted into a pSG5 vector (Stratagene) at the BglII site. The correct orientation of the inserted cDNA was verified by brief restriction mapping. A double mutant (PMLprb-nls-) was created by deleting the SmaI-MluI fragment of PMLprb- (this fragment harbors the nuclear localization signal domain). Correct joining of each clone was confirmed by DNA sequencing.


Figure 1: Schematic showing the structural features of wild-type PML protein and its mutants.



DNA Sequence Analysis of the PML Mutants

Sequencing of the mutant PML plasmids was performed as described previously(8) .

In Vitro Transcription and Translation

In vitro transcription of the PML mutant plasmids in the expression vector pSG5 was performed with T7 RNA polymerase using an RNA transcription kit obtained from Stratagene. In vitro translation was done by incorporating [S]methionine (1,200 Ci/mmol) (DuPont NEN) into proteins using a rabbit reticulocyte lysate in vitro translation system obtained from Life Technologies, Inc. In vitro translated proteins were electrophoresed in an SDS-10% polyacrylamide gel, dried, and autoradiographed.

Gene Transfection

For high efficiency transfection of the PML mutant plasmids into the NIH3T3 cells, lipofectamine-mediated gene transfers were performed according to the manufacturer's instructions (lipofectamine was purchased from Life Technologies, Inc.). To study the effect of PML and its mutants on transformation of NIH3T3 cells by activated neu oncogene, a modified calcium phosphate coprecipitation method was used. In this transfection assay, 2 µg of pSV2lacZ was included in all transfection experiments to monitor transfection efficiency.

Briefly, exponentially growing cells were trypsinized, seeded at 5 times 10^5 cells per 10-cm plate, and incubated overnight in 10 ml of complete Dulbecco's modified Eagle's medium. Then, 10-20 µg of plasmid DNA premixed with 0.5 ml of 0.25 M CaCl(2), 0.5 ml of 2 times Hanks' buffered solution (50 mM Hepes, 280 mM NaCl, 1.5 mM Na(2)HPO(4), pH 7.04 ± 0.02) was added, and the mixture was incubated for 15-20 min at room temperature. Calcium phosphate-DNA solution (1 ml) was added dropwise to the plate of cells, after which the mixture was swirled gently and incubated for 16-24 h at 37 °C under 5% CO(2). The medium was removed, and the cells were rinsed twice with growth medium, refed, and incubated for 24 h at 37 °C under 5% CO(2). The cells were split at a 1:10 ratio for focus-forming assay.

Focus-forming Assay

A focus-forming assay of NIH3T3 cells was performed as described in our previous reports(18) . Foci were visualized after 12-14 days of incubation by staining with 0.5% crystal violet in 25% methanol.

Immunofluorescence Staining and Western Blotting

The mutant plasmids were transfected into NIH3T3 cells by lipofectamine-mediated gene transfer according to the manufacturer's instructions. Total protein was isolated after 48 h of culture. Protein fractions isolated from the NIH3T3 cells transfected with different mutant PMLs were then subjected to immunofluorescence staining and Western blotting using the affinity-purified antipeptide antibody as described in our previous reports(19, 25) .


RESULTS

Characterization of PML Deletion Mutants

The major features of the PML protein (Fig. 1) include the proline-rich domain at the N-terminal, which resembles the transactivating domain of some transcription factors(7, 20, 26) . A RING finger motif, B-box-1, and B-box-2 lie immediately downstream. Other important domains include the alpha-helical domain responsible for dimerization, a nuclear localization signal, and a proline-serine-rich domain at the C-terminal believed to be involved in PML phosphorylation. In each mutant PML constructed by us as shown in Fig. 1and as described under ``Materials and Methods,'' the deleted region was confirmed by direct DNA sequencing. For mutants PMLpro-, PMLpr-, and PMLprb-, the 5`-ends of these clones were sequenced, and the presence of the correct ATG translation start site and the perfect Kozak's sequence was confirmed in each clone.

To confirm that these mutant clones would translate their respective mutant PML proteins, each of these plasmids were transfected into NIH3T3 cells by lipofectamine-mediated gene transfer. Western blot analysis of protein fractions isolated from these cells indicated that PMLdim- and PMLnls- encoded mutant PML proteins of the expected size (approximately 80-90 kDa) (Fig. 2A, lanes 6 and 7). However, mutant PMLpro-, PMLpr-, and PMLprb- encoded mutant proteins significantly smaller than expected. We have previously reported that although its predicted size is about 72 kDa, the PML protein migrates at about 90 kDa during SDS-polyacrylamide gel electrophoresis, probably due to its acidic nature(18) . As shown in Fig. 2A, lane 2, PMLpro- with a deletion of the first 48 amino acids migrated at about 70 kDa, indicating that is much smaller than the wild-type PML. To confirm that there is no additional deletion within the cDNA sequence, we completely sequenced one strand of PMLpro- and found no deletion in any other region of the cDNA. We speculate that the significant difference in size between PMLpro- and PML is the result of a change in secondary structure. The proline-rich domain may be responsible for the slower running nature of the wild-type PML in SDS-polyacrylamide gel electrophoresis. This notion is supported by the fact that both PMLpr- and PMLprb- migrated at molecular weights agreeable with their predicted sizes (Fig. 2A, lanes 3-5).


Figure 2: Expression of mutant PML proteins in NIH3T3 cells. The NIH3T3 cells were transfected with the various PML mutant plasmids by lipofectamine (Life Technologies, Inc.). Total protein was isolated after 48 h of culture, and Western blotting was performed as described previously(18) . A, lane 1, wild-type PML; lane 2, PMLpro-; lane 3, PMLpr-; lanes 4 and 5, PMLprb-; lane 6, PMLdim-; lane 7, PMLnls-. B, in vitro transcription and translation of the PML mutant plasmids. In vitro transcription and translation were performed as described previously(18) . Lane 1, wild-type PML; lane 2, PMLpro-; lane 3, PMLpr-; lane 4, PMLprb-; lane 5, pSG5 (an empty vector used as a negative control). Protein size markers are indicated on the left of both panels in kilodaltons.



To further confirm these findings, the PML mutant plasmids were transcribed and translated in vitro. Fig. 2B showed that the molecular weights of the in vitro transcribed and translated PMLpro-, PMLpr-, PMLprb-, and PMLdim- proteins agree with those derived from the Western blotting analysis as shown in Fig. 2A.

Cellular Localization of PML Mutant Proteins

Since PML had been shown to concentrate within PODs(16, 17, 22, 25) , we intended to define which domains of PML are required for the formation of PODs. How deleting various domains of PML affects its cellular localization was determined by transfecting the PML mutants into NIH3T3 cells. The PML mutant proteins were visualized in the cell by immunofluorescence staining using the affinity-purified PML antibody as described in our previous reports(18, 19) . As shown in Fig. 3, d and h, PMLpro- and PMLsp- did not affect the cellular location of PML. A typical nuclear speckled pattern made up of PODs was found in cells transfected with these plasmids. Deletion of the region harboring the nuclear localization signal resulted in cytoplasmic and perinuclear localization (Fig. 3b), presumably because the PML mutant protein could not enter the nucleus. A similar pattern of cellular distribution of PMLdim-, PMLpr-, and PMLprb- was found in NIH3T3 cells transfected with these plasmids. A diffuse instead of speckled nuclear pattern was found (Fig. 3, c, e, and f). The double mutant (PMLprb-nls-), unlike PMLnls-, was diffused throughout the cytoplasm (Fig. 3g). Since only an additional deletion of the RING finger motif in PMLprb-nls-, it is suggested that the RING finger motif may be responsible for interaction with other protein factors and that its deletion disrupts the perinuclear pattern. Together, the above results indicate that the dimerization domain, the RING finger domains, and the nuclear localization signal are all required for the organization of PODs, since deletion of these regions resulted in diffuse nuclear distribution and the inability of PMLs to assemble into POD.


Figure 3: Cellular distribution of PML and its mutants in transfected NIH3T3 cells. NIH3T3 cells transfected with 2-3 µg of the respective plasmids by lipofectamine were cultured for 48 h, and immunofluorescence staining was performed as described previously(19) . a, negative control; b, PMLnls-; c, PMLdim-; d, PMLpro-; e, PMLpr-; f, PMLprb-; g, double mutant (PMLprb-nls-); h, PMLsp-. Magnification, times1000.



Effect of PML Mutants on Suppression of Transformation of NIH3T3 Cells by Activated neu

In our previous report(19) , we demonstrated that PML suppresses neu-transformed NIH3T3 cells by suppressing both the expression of neu and its signaling events. To investigate the ability of these PML mutants to suppress transformation of NIH3T3 cells, each individual mutant was cotransfected with c-Neu104 (genomic neu) by calcium phosphate coprecipitation as described under ``Materials and Methods.''

Results of these studies (Fig. 4) showed that PMLdim-, PMLnls-, PMLpr-, PMLprb-, and PMLprb-nls- lost their ability to suppress transformation of NIH3T3 by activated neu. This suggests that the dimerization domain, nuclear localization signal, and RING finger motif are all required for the PML growth suppressor function. As shown in Fig. 3, all of these PML mutants share one common property, i.e. they are unable to assemble into a nuclear speckled pattern or the PODs. This suggests that the ability of PMLs to organize into PODs is required for PML to exert its growth or transformation suppressor function. This notion is supported by the finding that PML mutants PMLpro- and PMLsp-, which are capable of forming PODs (Fig. 3, a and d), were both able to suppress neu-induced transformation of NIH3T3 cells, just like the wild-type PML (Fig. 4).


Figure 4: The effect of mutant PMLs on suppression of neu-induced transformation of NIH3T3 cells. Cotransfection of plasmids by calcium phosphate coprecipitation and focus-forming assays were performed as described previously(18) . In each transfection assay, 10 µg of plasmid was transfected. The results shown represent means of three independent experiments with three plates each. In each transfection, 2 µg of pSV-betaGal (beta-galactosidase cDNA under the control of the SV40-early promoter) was included, and the activity of beta-galactosidase was determined to monitor transfection efficiency. Plasmid c-neu104 containing the activated neu oncogene has been described previously(18) ; PML and its mutants used in the study are described in Fig. 1.



PMLprb-, PMLnls-, and PMLprb-nls- as Potential Dominant Negative Inhibitors of PML

PML-RARalpha reportedly plays a critical role in APL as a dominant negative inhibitor of the normal PML and RXR function; the fusion protein acts by forming PML-RARalphabulletPML and PML-RARalphabulletRXR heterodimers through the dimerization domain of PML and RARalpha(15, 16, 17) . To investigate the effect of mutant PMLs on human cells that normally express wild-type PML, pPMLprb-, pPMLnls-, and pPMLprb-nls- were transfected into GM637D cells, an SV40-transformed human fibroblast cell line, by lipofectamine according to the procedures recommended by the manufacturer (Life Technologies, Inc.). In GM637D cells, PMLprb- displayed a diffuse nuclear pattern (Fig. 5b) without the typical POD pattern (Fig. 5a). PMLnls accumulated outside the nucleus, mostly in the perinuclear zone (Fig. 5d). Interestingly, the double mutant PMLprb-nls- showed a diffuse but fine staining pattern throughout the cytoplasm (Fig. 5c), completely unlike those of PMLprb- and PMLnls-. Together, these results indicate that the expression of PMLprb-, PMLnls-, and PMLprb-nls- in GM637D cells led to a significant reduction or, in some cases, complete elimination of the PODs. This in turn suggests that PMLprb-, PMLnls-, and PMLprb-nls- are capable of sequestration PML from its normal cellular localization and are potential dominant negative inhibitors of the wild-type PML.


Figure 5: Cellular localization patterns of PML in human fibroblast GM637D cells. The GM637D cells were transfected with 2-3 µg of the PML mutant plasmid constructs by lipofectamine (Life Technologies, Inc.). After 48 h of culture, immunofluorescence staining was performed as described previously(19) . a, wild-type PML; b, PMLprb-; c, double mutant (PMLprb-nls-); d, PMLnls-. Magnification, times1000.



The dominant negative inhibitory effect of PMLprb-, PMLnls-, and PMLprb-nls- were further demonstrated by their ability to inhibit the biologic function of the wild-type PML. As shown in Fig. 6, PMLprb-, PMLnls-, and PMLprb-nls- were remarkably capable of knocking out the ability of wild-type PML to suppress transformaton of NIH3T3 cells by activated neu. This inhibition is similar to that caused by the PML-RARalpha fusion protein encoded from the breakpoint of the t(15;17) translocation in APL(18) . Furthermore, PMLprb- and PMLprb-nls- inhibited PML function in a dose-dependent manner (data not shown).


Figure 6: PMLprb-, PMLnls-, and PMLprb-nls- as potential dominant negative inhibitors of the wild-type PML. Cotransfection of plasmids by calcium phosphate coprecipitation and focus-forming assays were performed as described previously(18) . In each transfection assay, 10 µg (unless otherwise specified in parentheses) of plasmid was transfected. The results shown represent the means of three independent experiments with three plates each. Plasmid pSV-betaGal was included, and the activity of beta-galactosidase was determined to monitor transfection efficiency.




DISCUSSION

To understand the function of PML, a growth suppressor involved in the t(15;17) translocation in APL, we constructed several mutant plasmids and used them to analyze its functional domains. We found that (i) the nuclear localization signal, dimerization domain, and RING finger motif of PML are all essential for the formation of PODs; (ii) the ability of PML to form PODs in vivo is required for its growth suppressor function; and (iii) PMLprb-, PMLnls-, and PMLprb-nls- are potential candidates for dominant negative inhibition of the wild-type PML. Moreover, we have uncovered evidence that the RING finger motif of PML may interact with other proteins.

The PML protein contains several important domains, including a C3HC4 (3 Cys, 1 His, and 4 Cys) zinc-finger motif (RING finger domain); two additional Cys/His regions, referred to as B-box-1 and B-box-2; and an alpha-helical coiled-coil region(21, 26, 27, 28) . Immunofluorescence staining demonstrated that PML is a major component of novel nuclear bodies designated PODs(17, 20, 26) . We have conclusively demonstrated that the nuclear localization signal, the dimerization domain, and the RING finger motif of PML, but not the proline-rich domain at the N-terminal and the serine-proline-rich domain at the C-terminal, are required for the formation of PODs. Our results, as shown in Fig. 3, e and f, agree with the observation of Kastner et al.(7) that PML proteins bearing a mutation in the cysteine-rich (RING finger) motif (Glu-Cys Glu-Leu) had a diffuse nuclear staining pattern. During the preparation of this manuscript, Borden et al.(29) also demonstrated by site-directed mutagenesis that the RING finger motif of PML is necessary for POD formation.

In our previous reports, we showed that PML is a growth and transformation suppressor(18, 19) . In this study, we demonstrated that the RING finger motif, dimerization domain, and nuclear localization signal are responsible for this suppression of growth and transformation. Since these regions of PML are also required for the formation of PODs, we therefore concluded that the ability of PML to assemble into PODs is essential for the growth suppression effect of PML. This finding is corroborated by the observations that ATRA-induced differentiation of NB4 and APL cells is associated with a reorganization of the microspeckled nuclear pattern into PODs and that no such response was found in the ATRA-resistant NB4 cells(16, 17, 22) .

At present, the composition and function of PODs is not completely understood. Our finding that PML is a growth and transformation suppressor sheds new light on the in vivo biologic function of this new form of nuclear body. PODs, which are associated with the nuclear matrix, reportedly do not contain any of the proteins known to be involved in pre-mRNA splicing, transcription, and DNA synthesis (17, 30) . In addition to PML, the PODs may include the SP100, NDP-55, and Vmw110 (also known as ICP0) proteins and an unidentified 65-kDa protein(16, 17, 21, 22, 30) . These proteins, however, do not directly interact with PML. In studies of APL and herpes simplex virus immediate-early protein, PODs appeared to be extremely important (both directly and indirectly) for myeloid differentiation as well as regulation of gene expression (e.g. activation of both cellular and viral genes in infection)(16, 17, 21, 22, 30, 31) .

Recently, the growth suppressor function of PML was confirmed by another group, who found that when skin, breast, and colon malignant cells turned invasive, PML expression was lost(32) . These data imply that PML may be an antioncogene involved not only in APL but also in non-hematological oncogenesis. Interestingly, Terris et al.(33) reported that expression of PML increased significantly in the inflammatory tissues and during normal or pathological proliferative states, indicating that PML plays a role in the inflammatory process and in cell growth control.

As stated above, the PML-RARalpha fusion protein is reportedly a dominant negative inhibitor of PML and RXR(7, 17, 34) . Previous immunofluorescence staining of PML indicated cytoplasmic and/or nuclear localization with a micropunctuated pattern in APL blasts and in cells stably transfected with PML-RARalpha. Here, we have demonstrated that PMLprb-, PMLnls-, and PMLprb-nls- are potential dominant negative inhibitors against the normal function of PML and that transient expression of PMLprb-, PMLnls-, and PMLprb-nls- significantly reduces or completely eliminates normal PODs in GM637D cells. Furthermore, we have shown that PMLprb-, PMLnls-, and PMLprb-nls- can block the effect of wild-type PML on transformation of NIH3T3 cells by activated neu. We have noticed that stable transfectants overexpressing PMLnls- in GM637D cells eventually died (data not shown). Since overexpression of PML in B104-1-1 (19) and HeLa cells (^2)did not result in cell death, we therefore reason that PMLnls- probably induced the observed cell death through its perinuclear localization. It is possible that the RING finger motif interacts with other important unknown proteins essential for cell growth. Sequestration of these proteins by PMLnls- may be responsible for the cell death. Therefore, PMLnls- may not be a suitable dominant negative inhibitor. Conversely, PMLprb- and PMLprb-nls-, both without the RING finger motif, should be more suitable for testing the effect of knocking out wild-type PML in normal cells and for studying whether elimination of cellular PML will result in growth stimulation. We plan to establish in our laboratory stable transfectants of GM637D constitutively expressing the PMLprb- and PMLprb-nls- and to investigate the effects of these dominant negative inhibitors on proliferation and growth of GM637D cells. Such studies will be helpful in further understanding the function of PML in the control of cell growth.

As stated above, PML is characterized by the RING finger motif. This motif has the sequence C(1)-X(2)-C(2)-X-C(3)-X-H(1)-X(2)-C(4)-X(2)-C(5)-X-C(6)-X(2)-C(7), where C represents cysteine, H represents histidine, X can be any amino acid, and the numbers in parentheses refer to the length in amino acids of the sequences(20, 27) . The RING finger motif may play a important cellular role by acting as a DNA binding or protein-protein interacting domain(9, 20, 29) . It is necessary then to determine whether DNA or protein is involved in the interaction with the RING finger motif of PML protein. The fact that treatment of the nuclei with RNase and DNase in previous studies did not disrupt the PODs in human cell lines suggests that nucleic acids are not a component of this structure (30) . (^3)Consequently, this implies that it is the RING finger motif that normally interacts with protein factors. Our results presented in Fig. 3and Fig. 4show that the immunostaining pattern of mutant PMLnls- is clearly distinct from that of double mutant PMLprb-nls- and that PMLnls- accumulated in the cytoplasm, mostly in the perinucleus. In contrast, the staining pattern of the double mutant was fine and diffuse throughout the cytoplasm. This suggests that the RING finger motif accounts for these differences. We therefore speculate that the RING finger motif of PML interacts with other nuclear protein factors and is responsible for the differences in cellular distribution between PMLnls- and PMLprb-nls-.

We conclude then that the RING finger motif, alpha-helical region, and nuclear localization signal of PML are all required for the formation of PODs. We also conclude that the ability of PML to form PODs is essential for its growth and transformation suppressor function. However, studies are needed (i) to define more precisely the specific contribution of each domain in PML and (ii) to define the composition and function of PODs so as to understand in depth their role during human oncogenesis. In this direction, we have been assessing the effects of the two dominant negative inhibitors of wild-type PML described in this report (PMLprb- and PMLprb-nls-) on the proliferation and differentiation of GM637D cells, which stably express mutant PMLs.


FOOTNOTES

*
This study was supported by Grant CA55577 from the National Institutes of Health (to K.-S. C.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Div. of Laboratory Medicine, Box 72, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030. Tel.: 713-792-2581; Fax: 713-794-1800.

(^1)
The abbreviations used are: APL, acute promyelocytic leukemia; POD, PML oncogenic domains; ATRA, all-trans-retinoic acid; RXR, retinoic X receptor; RARalpha, retinoic acid receptor-alpha.

(^2)
X.-F. Le, P. Yang, and K.-S. Chang, unpublished results.

(^3)
X.-F. Le, P. Yang, and K.-S. Chang, unpublished observations.


ACKNOWLEDGEMENTS

We thank You-Hong Fan and Guo-Zeng Ma for technical assistance. We are also grateful to Jude Richard for critical reading of the manuscript. Peptide synthesis facilities used in the production of antipeptide antibody and animal care facilities were supported by NCI Core Grant CA-16672 (to M. D. Anderson Cancer Center).


REFERENCES

  1. Rowley, J. D., Golomb, H. M., and Dougherty, C. (1977) Lancet 1, 549-550 [Medline] [Order article via Infotrieve]
  2. Borrow, J., Goddard, A. D., Sheer, D., and Solomon, E. (1990) Science 249, 1577-1580 [Medline] [Order article via Infotrieve]
  3. de The, H., Chomienne, C., Lanotte, M., Degos, L., and Dejean, A. (1990) Nature 347, 558-561 [CrossRef][Medline] [Order article via Infotrieve]
  4. Alcalay, M. D., Zangrilli, D., Pandolfi, P. P., Longo, M., Mencarelli, A., Gaicomucci, A., Rocchi, M., Biondi, A., Rambaldi, A., LoCoco, F., Diverio, D., Donti, E., Grignani, F., and Pelicci, P. G. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 1977-1981 [Abstract]
  5. Kakizuka, A., Miller, W. H., Jr., Umesono, K., Warrell, R. P., Jr., Frankel, S. R., Murty, V. V. V. S., Dmitrovsky, E., and Evans, R. M. (1991) Cell 66, 663-674 [Medline] [Order article via Infotrieve]
  6. de The, H., Lavau, C., Marchio, A., Chomienne, C., Degos, L., and Dejean, A. (1991) Cell 66, 675-684 [Medline] [Order article via Infotrieve]
  7. Kastner, P., Perez, A., Lutz, Y., Rochette-Egly, C., Gaub, M. P., Durand, B., Lanotte, M., Berger, R., and Chambon, P. (1992) EMBO J. 11, 629-642 [Abstract]
  8. Chang, K. S., Stass, S. A., Chu, D. T., Deaven, L. L., Trujillo, J. M., and Freireich, E. J. (1992) Mol. Cell. Biol. 12, 800-810 [Abstract]
  9. Pandolfi, P. P., Grignani, F., Alcalay, M., Mencarelli, A., Biondi, A., LoCoco, F., Grignani, F., and Pelicci, P. G. (1991) Oncogene 6, 1285-1292 [Medline] [Order article via Infotrieve]
  10. Goddard, A. D., Borrow, J., Freemont, P. S., and Solomon, E. (1991) Science 254, 1371-1374 [Medline] [Order article via Infotrieve]
  11. Alcalay, M., Zangrilli, D., Fagioli, M., Pandolfi, P. P., Mencarelli, A., Lo Coco, F., Biondi, A., Grignani, F., and Pelicci, P. G. (1992) Proc. Natl. Acad. U. S. A. 89, 4840-4844 [Abstract]
  12. Grignani, F., Ferrucci, P. F., Testa, U., Talamo, G., Fagioli, M., Alcalay, M., Mencarelli, A., Grignani, F., Peschle, C., Nicoletti, I., and Pelicci, P. G. (1993) Cell 74, 423-431 [Medline] [Order article via Infotrieve]
  13. Grignani, F., Testa, U., Fagioli, M., Barberi, T., Masciulli, R., Mariani, G., Peschle, C., and Pelicci, P. G. (1995) Cancer Res. 55, 440-443 [Abstract]
  14. Testa, U., Grignani, F., Barberi, T., Fagioli, M., Masciulli, R., Ferrucci, P. F., Seripa, D., Camagna, A., Alcalay, M., Pelicci, P. G., and Peschle, C. (1994) Cancer Res. 54, 4508-4515 [Abstract]
  15. Perez, A., Kastner, P., Sethi, S., Lutz, Y., Reibel, C., and Chambon, P. (1993) EMBO J. 12, 3171-3182 [Abstract]
  16. Weis, K., Rambaud, S., Lavau, C., Jansen, J., Carvalho, T., Carmo-Fonseca, M., Lamond, A., and Dejean, A. (1994) Cell 76, 345-356 [Medline] [Order article via Infotrieve]
  17. Dyck, J. A., Maul, G. G., Miller, W. H., Jr., Chen, J. D., Kakizuka, A., and Evans, R. M. (1994) Cell 76, 333-343 [Medline] [Order article via Infotrieve]
  18. Mu, Z. M., Chin, K. V., Liu, J. H., Lozano, G., and Chang, K. S. (1994) Mol. Cell. Biol. 14, 6858-6867 [Abstract]
  19. Liu, J. H., Mu, Z. M., and Chang, K. S. (1995) J. Exp. Med. 181, 1965-1973 [Abstract]
  20. Freemont, P. S., Hanson, I. M., and Trowsdale, J. (1991) Cell 64, 483-484 [Medline] [Order article via Infotrieve]
  21. Everett, R. D., and Maul, G. G. (1994) EMBO J. 13, 5062-5069 [Abstract]
  22. Koken, M. H. M., Puvio-Dutilleul, F., Guillemin, M. C., Viron, A., Linares-Cruz, G., Stuurman, N., de Jong, L., Szostecki, C., Calvo, F., Chomienne, C., Degos, L., Puvion E., and de The, H. (1994) EMBO J. 13, 1073-1083 [Abstract]
  23. Kozak, M. (1986) Cell 44, 283-292 [Medline] [Order article via Infotrieve]
  24. Barnes, W. M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 2216-2220 [Abstract]
  25. Chang, K.-S., Fan, Y. H., Andreeff, M., Liu, J., and Mu, Z. M. (1995) Blood 85, 3646-3653 [Abstract/Free Full Text]
  26. Reddy, B. A., Etkin, L., and Freemont, P. S. (1992) Trends Biochem. Sci. 17, 344-345 [CrossRef][Medline] [Order article via Infotrieve]
  27. Freemont, P. S. (1993) Ann. N. Y. Acad. Sci. 684, 174-192 [Medline] [Order article via Infotrieve]
  28. Reddy, B. A., Kloc, M., and Etkin, L. (1991) Dev. Biol. 148, 107-116 [Medline] [Order article via Infotrieve]
  29. Borden, K. L. B., Boddy, M. N., Lally, J., O'Reilly, N. J., Martin, S., Howe, K., Solomon, E., and Freemont, P. (1995) EMBO J. 14, 1532-1541 [Abstract]
  30. Ascoli, C. A., and Maul, G. G. (1991) J. Cell Biol. 112, 785-795 [Abstract]
  31. Zhu, Z., Cai, W. Z., and Schaffer, P. A. (1994) J. Virol. 68, 3027-3040 [Abstract]
  32. Koken, M. H. M., Linares-Cruz, G., Quignon, F., Viron, A., Chelbi-Alix, M., Sobczak-Thepot, J., Juhlin, L., Degos, L., Calvo F., and de The, H. (1995) Oncogene 10, 1315-1324 [Medline] [Order article via Infotrieve]
  33. Terris, B., Baldin, V., Dubois, S., Degott, C., Flejou, J. F., Henin, D., and Dejean, A. (1995) Cancer Res. 55, 1590-1597 [Abstract]
  34. Daniel, M. T., Koken, M., Romagne, O., Barbey, S., Bazarbachi, A., Stadler, M., Guillemin, M. C., Degos, L., Chomienne, C., and de The, H. (1993) Blood 82, 1858-1867 [Abstract]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.